Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML

NCT05662904 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Relapsed/Refractory Acute Myeloid Leukemia (AML)

Interventions

BIOLOGICAL: Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion
DRUG: Gemtuzumab Ozogamicin

Sponsor

German Cancer Research Center

Collaborators

[object Object]
[object Object]